Market Insight – The promise of orexin antagonists
This article was originally published in Scrip
Executive Summary
July's announcement of a $146 million-plus deal between GlaxoSmithKlineand the Swiss biopharmaceutical companyActelion, to collaborate on the development and commercialisation of orexin antagonist almorexant, has thrown the whole area of orexin research under the spotlight. Almorexant is in Phase III trials as a treatment for primary insomnia, but the potential applications of orexin antagonists extend beyond just the management of sleep disturbances.